Ποια είναι η τιμή για OncoCyte Corporation (OCX)

Η τιμή για OncoCyte Corporation (OCX) είναι $2.84

Ποια είναι η κεφαλαιοποίηση αγοράς για OncoCyte Corporation (OCX)

Η κεφαλαιοποίηση αγοράς για OncoCyte Corporation (OCX) είναι $729.71K

OncoCyte Corporation (OCX) Τιμή και Κεφαλαιοποίηση Αγοράς

OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.

Η τιμή για OCX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$21,287,218 $729.71K	NVDA	$5.470T	+749,549,827.53%
$17,385,659 $729.71K	AAPL	$4.467T	+612,170,988.78%
$16,246,541 $729.71K	GOOG	$4.174T	+572,061,219.52%
$14,400,550 $729.71K	MSFT	$3.700T	+507,061,518.69%
$11,108,985 $729.71K	AMZN	$2.854T	+391,161,356.49%

Η τιμή για OCX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$21,287,218 $729.71K